Screening with carcinoembryonic antigen (CEA) levels in the blood has also been shown to have poor sensitivity (36%–74%, based on the stage of CRC).[10] Therefore, the identification and confirmation of noninvasive or minimally invasive circulating biomarkers for CRC disease progress and remission, and cancer prognosis remains a quandary, prompting an investigation in CRC biomarker research. This evidence concerns the gene CEACAM5 and colorectal carcinoma.